Publicacions en què col·labora amb MIGUEL JOSÉ MARTÍN JIMÉNEZ (38)

2022

  1. A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol

    BMC Psychiatry, Vol. 22, Núm. 1

  2. HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

    Cancers, Vol. 14, Núm. 3

  3. How we treat HR-positive, HER2-negative early breast cancer

    Future oncology (London, England), Vol. 18, Núm. 8, pp. 1003-1022

  4. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

    The Lancet. Oncology, Vol. 23, Núm. 1, pp. 149-160

  5. The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0

    Supportive Care in Cancer, Vol. 30, Núm. 8, pp. 6745-6754

2021

  1. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

    Scientific Reports, Vol. 11, Núm. 1

  2. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

    Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681

  3. Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach

    Journal of Personalized Medicine, Vol. 11, Núm. 8

  4. Technical challenges for CTC implementation in breast cancer

    Cancers, Vol. 13, Núm. 18

2020

  1. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

  2. Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 717-724

2019

  1. Concordance of genomic variants in matched primary breast cancer, metastatic tumor, and circulating tumor DNA: The Mirror study

    JCO Precision Oncology, Vol. 3

  2. Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii91-viii92

  2. Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)

    Breast Cancer Research and Treatment

  3. Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit

    Journal of Genetic Counseling, Vol. 27, Núm. 4, pp. 854-862

  4. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

    Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634

  5. Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene

    Cancer Management and Research, Vol. 10, pp. 4517-4522

2017

  1. Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital

    Oncology (Switzerland), Vol. 92, Núm. 2, pp. 68-74

  2. Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study

    PLoS ONE, Vol. 12, Núm. 10